Summary of Key Points from the Conference Call Industry Overview - **Sector**: China's healthcare sector, specifically focusing on Biotech/Pharma and CRO/CDMO segments - **Trend**: Transitioning from "go-global beta" to "visibility-driven alpha" as the sector shows robust performance in 2025, driven by emerging assets expanding globally [1][2] Core Insights - **Investment Strategy Shift**: Investors are moving from beta trades based on licensing expectations to focusing on tangible execution and visibility into key data readouts and earnings delivery for 2026 [1][2] - **CRO/CDMO Outlook**: Positive outlook for CDMOs due to accelerated growth, strong product cycles, and reasonable valuations. Upgrades for WuXi AppTec and WuXi XDC to "Buy" [2][11] - **Biotech/Pharma Selectivity**: A more selective approach is advised, favoring companies with validated early data and realistic deal expectations. Preferred stocks include Kelun Biotech, Henlius, and Hansoh [2][7] - **MedTech Neutral Stance**: Cautious outlook on MedTech, with a recommendation to buy AngelAlign and Weigao, while maintaining a neutral stance overall [2][7] - **Healthcare Services Caution**: Downgraded outlook for healthcare services due to cost control measures and weak consumption cycles, with downgrades for Hygeia and Jinxin [2][7] Emerging Technologies - **AI and New Modalities**: Anticipated advancements in AI within healthcare and a strengthening of China's leadership in new modalities such as next-gen ADCs and innovative oligonucleotide medicines [3][7] - **Surgical Robotics**: 2026 is expected to be pivotal for surgical robotics commercialization, driven by new national billing rules [3] Financial Metrics and Projections - **Earnings Estimates**: EPS estimates for Chinese CDMOs/CROs revised up by 3%-4% for FY26-27 due to improved earnings visibility [11] - **Capex Normalization**: Capital expenditure is returning to growth levels, focusing on high-potential modalities and overseas expansion [10][21] - **Valuation Recovery**: Valuations for WuXi AppTec and WuXi XDC are expected to recover modestly as visibility improves, although they still trade at a discount compared to global peers [10][14] Market Dynamics - **Geopolitical Sensitivity**: Market sensitivity to geopolitical headlines has decreased, with a clearer distinction between sentiment risk and actual business impact [10][27] - **Outsourcing Trends**: Despite geopolitical uncertainties, outsourcing rates are expected to rise, driven by cost efficiency and access to specialized technologies [28] Key Risks and Considerations - **Biosecure Act Impact**: The Biosecure Act's implications are being closely monitored, with expectations that any structural reallocation of outsourcing away from China will be gradual [42] - **Client Behavior**: Client concerns regarding the Biosecure Act have diminished, with high retention rates noted for WuXi's services [13] Conclusion - The healthcare sector in China is poised for a significant transformation as it shifts towards visibility-driven investments. Key players in the CDMO and Biotech/Pharma segments are expected to benefit from improved earnings visibility and a supportive funding environment, while caution remains in MedTech and healthcare services due to ongoing economic pressures.

Group 1 - CRO concept stocks have shown significant gains, with Weiya Bio rising by 6.14% to HKD 2.42, WuXi Biologics increasing by 6.01% to HKD 40.54, Tigermed up by 4.65% to HKD 56.3, and WuXi AppTec rising by 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's net profit is projected to grow by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that the CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend as innovative drug development heats up [1]

Group 1 - The CXO sector experienced a notable rebound in early 2026, primarily driven by domestic demand-focused CRO and experimental service companies, while leading CDMO companies with significant global exposure underperformed [2][25] - The current market activity reflects a short-term rebound rather than a comprehensive recovery of the CXO industry, with investors favoring easily confirmable segments [2][25] Group 2 - After a low in 2024, domestic innovative drug financing has improved, with policy expectations and order stability more evident in companies focused on domestic demand, while external demand CDMOs face a more complex pricing environment [4][27] - Despite overall industry sentiment improving, the market remains cautious towards CDMOs, which are seen as having the most certain fundamental recovery and highest order visibility [4][27] Group 3 - WuXi AppTec's 2025 performance forecast indicates a projected revenue of approximately 45.46 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 19.15 billion RMB, reflecting a significant growth of 102.65% [6][30] - The company's revenue guidance was adjusted upward multiple times throughout the year, indicating a continuous improvement in order conversion, project advancement, and capacity utilization [6][29] Group 4 - Market sentiment towards WuXi AppTec is complex, with a significant portion of profit growth attributed to non-recurring gains from asset disposals, leading to a cautious market outlook despite strong operational performance [7][30] - The market's valuation reflects skepticism not about 2025 performance but about the sustainability of growth beyond 2027 [7][30] Group 5 - Concerns regarding the future growth of TIDES and geopolitical risks are central to market pricing, indicating a focus on long-term growth potential rather than immediate performance [9][32] - The demand for TIDES products remains strong, with supply chain share increasing, suggesting that the challenges are more about supply capacity than demand saturation [11][34] Group 6 - WuXi AppTec's growth is characterized by a platform-based expansion rather than reliance on a single segment, with significant performance in small molecule D&M business [15][38] - The company has improved operational efficiency and capacity utilization without significant capital investment, enhancing its competitive position in the global pharmaceutical outsourcing industry [17][40] Group 7 - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand area, emphasizing the importance of time in meeting customer needs [19][41] - This acquisition reflects a broader trend of consolidation in the industry, where leading companies are increasingly focused on embedding themselves deeper into the global innovative drug supply chain [21][43] Group 8 - The current rebound in the CXO sector appears to be driven by sentiment and expectations rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [22][44] - The ongoing structural changes in the industry suggest that companies that have successfully adjusted their order and capability structures may see their value reassessed in the future [22][45]

Core Viewpoint - The China Securities Medical Index (399989) closed at 7161.62 points, up 0.6%, with a trading volume of 19.192 billion yuan and a turnover rate of 1.97% on February 9 [1] Group 1: Index Performance - On the same day, 37 of the index's constituent stocks rose, with Sanbo Brain Science leading with a 5.32% increase, while 12 stocks declined, with Aier Eye Hospital falling by 2.98% [1] - The top ten constituent stocks of the China Securities Medical Index are primarily in the pharmaceutical and medical sectors, with WuXi AppTec holding the highest weight at 10.03% [1] Group 2: Stock Details - The top ten stocks include: - WuXi AppTec: Weight 10.03%, Latest Price 98.70, Market Cap 294.97 billion yuan [1] - Mindray Medical: Weight 9.12%, Latest Price 189.17, Market Cap 229.36 billion yuan [1] - United Imaging Healthcare: Weight 7.49%, Latest Price 128.92, Market Cap 106.25 billion yuan [1] - Aier Medical: Weight 6.04%, Latest Price 10.74, Market Cap 100.16 billion yuan [1] - Other notable stocks include Tigermed, Kanglong Chemical, and Yuyue Medical, all within the medical and pharmaceutical industry [1] Group 3: Capital Flow - The net outflow of main funds from the index's constituent stocks totaled 205 million yuan, while retail investors saw a net inflow of 1.51 billion yuan [1] - Detailed capital flow indicates that major stocks like WuXi AppTec and Mindray Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Core Viewpoint - The recent rebound in the CXO sector is not indicative of a comprehensive recovery but rather a reaction to easily confirmable short-term improvements, particularly among domestic demand-driven CRO and experimental service companies, while leading CDMO companies focused on external demand have underperformed [3][4][5]. Market Dynamics - The market is currently trading based on short-term rebounds rather than a long-term recovery in the CXO industry, with a notable divergence in performance between domestic-focused companies and those reliant on global demand [4][5]. - Despite an overall positive sentiment in the industry, caution remains regarding CDMO companies, which are facing complex pricing environments and geopolitical uncertainties that could impact long-term growth [5][12]. Financial Performance - WuXi AppTec's 2025 performance forecast indicates a revenue of approximately 454.56 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 191.51 billion RMB, reflecting a significant growth of 102.65% [7]. - The company's revenue growth trajectory has shown consistent improvement throughout the year, with a core business revenue increase of approximately 21.40%, indicating enhanced growth momentum post-divestiture of certain business segments [9][10]. Market Sentiment and Valuation - The market's cautious stance towards CDMO companies is driven by uncertainties regarding future growth, particularly in relation to geopolitical risks and the sustainability of demand for emerging business lines like TIDES [12][13]. - The valuation of CDMO companies reflects a conservative outlook on long-term growth potential rather than immediate revenue uncertainties, leading to a disconnect between fundamental recovery and stock price performance [10][28]. Structural Changes in the Industry - The growth in WuXi AppTec's small molecule D&M business is attributed to an expansion in order structure and capabilities, moving beyond traditional roles to encompass more complex production processes [20][22]. - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand sector, emphasizing the importance of time as a critical resource in the competitive landscape [24][26]. Conclusion - The current rebound in the CXO sector appears to be driven by emotional and anticipatory factors rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [28][29].

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

Core Viewpoint - Multiple A-share pharmaceutical companies have announced their 2025 performance forecasts, with 160 stocks expected to see year-on-year growth in net profit attributable to shareholders, particularly within the CXO sector, which shows robust performance and is anticipated to recover overall due to a more favorable external environment and a rebound in investment and financing [1][7]. Group 1: Company Performance - WuXi AppTec (603259.SH/2359.HK) is expected to lead in performance growth, forecasting a net profit attributable to shareholders of 19.151 billion yuan, with a non-recurring net profit of 13.241 billion yuan, reflecting a year-on-year increase of 32.6%, surpassing historical peaks [1][8]. - The company has raised its full-year revenue guidance twice in 2025, now projecting total revenue of approximately 45.456 billion yuan, a year-on-year increase of about 15.84%, with sustainable business revenue expected to grow by approximately 21.4% [2][9]. Group 2: Business Model and Growth Drivers - The unique value of WuXi AppTec's "integrated, end-to-end" CRDMO business model has significantly contributed to its performance, with over 430,000 compounds delivered in the drug discovery phase and 621 new molecules entering the D&M pipeline in 2025 [2][9]. - The number of small molecule drugs in Phase III and commercialization has increased from 107 to 167 from 2022 to the third quarter of 2025, representing a 56% year-on-year growth, with corresponding revenue growth exceeding 150% [4][11]. Group 3: Shareholder Returns - WuXi AppTec has emphasized sharing its growth with shareholders, having returned nearly 20 billion yuan through cash dividends and share buybacks over seven years, accounting for over 40% of cumulative net profit [6][14]. - Based on a 30% cash dividend policy and the 2025 performance forecast, the cash dividend amount is expected to double year-on-year, enhancing shareholder returns [6][14].

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors needing to consider the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry will rely more on key data releases, actual transactions, and visibility on earnings realization or turning points [1] Group 2: Sector Insights - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Junshi Biosciences, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector is maintained with a neutral outlook, indicating that while the industry has bottomed out, recovery will take time [1] - Recommended stocks include Angelalign Technology and Weigao Group [1]

Group 1 - Morgan Stanley reduced its holdings in WuXi AppTec (02359.HK) by approximately 798,119 shares at a price of HKD 109.1481 per share, totaling around HKD 87.1132 million [1][2] - After the reduction, Morgan Stanley's remaining shares amount to approximately 35,245,132, representing a holding percentage of 6.90% [1][2] - The previous day, February 2, Morgan Stanley had increased its holdings by 1,490,412 shares at an average price of HKD 109.281, resulting in a holding percentage of 7.06% before the reduction [2]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]